06/17/2026
🚨 Big news for families facing a new type 1 diabetes diagnosis.
The FDA has approved Tzield for children ages 8–17 who have been newly diagnosed with type 1 diabetes.
So what does that mean?
When someone is diagnosed with type 1, their body may still be making a small amount of its own insulin. Tzield is a treatment that can help protect those remaining insulin-producing cells for longer.
Why does that matter?
Even a little insulin production can make a difference. Research shows it may help:
💙 Increase time in range
💙 Reduce low blood sugars
💙 Support easier diabetes management
💙 Lower the risk of some long-term complications
Because most children are diagnosed after type 1 diabetes has already developed, this new approval gives families another option during those early months after diagnosis.
This approval is also an important milestone in the journey toward a cure. By helping preserve the body's remaining insulin-producing cells, Tzield builds on decades of research aimed at stopping type 1 diabetes and one day eliminating it altogether.
Read more from the FDA: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-pediatric-stage-3-type-i-diabetes
